LGND Ligand Pharmaceuticals Inc

Price (delayed)

$144.73

Market cap

$2.41B

P/E Ratio

50.25

Dividend/share

N/A

EPS

$2.88

Enterprise value

$2.71B

Ligand Pharmaceuticals is a biopharmaceutical company located in San Diego, California. Founded in 1987 as Progenx Inc., the company went public in 1992.

Highlights
The revenue has surged by 99% year-on-year and by 21% since the previous quarter
The gross profit has surged by 79% year-on-year and by 12% since the previous quarter
Ligand Pharmaceuticals's quick ratio has shrunk by 76% YoY but it has surged by 67% QoQ
Ligand Pharmaceuticals's gross margin has decreased by 10% YoY and by 8% QoQ

Key stats

What are the main financial stats of LGND
Market
Shares outstanding
16.68M
Market cap
$2.41B
Enterprise value
$2.71B
Valuations
Price to earnings (P/E)
50.25
Price to book (P/B)
3.06
Price to sales (P/S)
9.58
EV/EBIT
50.08
EV/EBITDA
28
EV/Sales
10.78
Earnings
Revenue
$251.66M
EBIT
$54.2M
EBITDA
$96.95M
Free cash flow
$36.52M
Per share
EPS
$2.88
Free cash flow per share
$2.19
Book value per share
$47.23
Revenue per share
$15.11
TBVPS
$29
Balance sheet
Total assets
$1.26B
Total liabilities
$469.77M
Debt
$322.41M
Equity
$786.52M
Working capital
$358.4M
Liquidity
Debt to equity
0.41
Current ratio
7.83
Quick ratio
6.86
Net debt/EBITDA
3.1
Margins
EBITDA margin
38.5%
Gross margin
77.4%
Net margin
19%
Operating margin
26%
Efficiency
Return on assets
3.7%
Return on equity
6.5%
Return on invested capital
6.7%
Return on capital employed
4.5%
Return on sales
21.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

LGND stock price

How has the Ligand Pharmaceuticals stock price performed over time
Intraday
7.22%
1 week
5.77%
1 month
34.92%
1 year
53.72%
YTD
45.53%
QTD
10.32%

Financial performance

How have Ligand Pharmaceuticals's revenue and profit performed over time
Revenue
$251.66M
Gross profit
$194.83M
Operating income
$65.41M
Net income
$47.89M
Gross margin
77.4%
Net margin
19%
The net margin has soared by 197% YoY
The company's operating income has surged by 144% QoQ
Ligand Pharmaceuticals's operating margin has surged by 103% QoQ
The revenue has surged by 99% year-on-year and by 21% since the previous quarter

Growth

What is Ligand Pharmaceuticals's growth rate over time

Valuation

What is Ligand Pharmaceuticals stock price valuation
P/E
50.25
P/B
3.06
P/S
9.58
EV/EBIT
50.08
EV/EBITDA
28
EV/Sales
10.78
Ligand Pharmaceuticals's EPS has increased by 19% QoQ
LGND's P/B is 33% lower than its 5-year quarterly average of 4.6 but 13% higher than its last 4 quarters average of 2.7
The equity has grown by 13% year-on-year and by 5% since the previous quarter
The revenue has surged by 99% year-on-year and by 21% since the previous quarter
The price to sales (P/S) is 40% lower than the 5-year quarterly average of 16.0 and 4.2% lower than the last 4 quarters average of 10.0

Efficiency

How efficient is Ligand Pharmaceuticals business performance
Ligand Pharmaceuticals's ROIC has increased by 24% from the previous quarter
The ROA has increased by 19% QoQ
The company's return on equity rose by 18% QoQ
Ligand Pharmaceuticals's return on sales has decreased by 11% QoQ

Dividends

What is LGND's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LGND.

Financial health

How did Ligand Pharmaceuticals financials performed over time
The company's total assets is 167% higher than its total liabilities
Ligand Pharmaceuticals's quick ratio has shrunk by 76% YoY but it has surged by 67% QoQ
LGND's current ratio has dropped by 73% year-on-year but it has soared by 71% since the previous quarter
The debt is 59% less than the equity
The debt to equity has contracted by 38% YoY and by 16% from the previous quarter
The debt has contracted by 30% YoY and by 12% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.